Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study explores what matters most to patients with high-risk head and neck skin cancer

NCT ID NCT05482880

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how 78 patients with high-risk skin cancer on the head or neck felt about their treatment decisions, quality of life, and satisfaction with care. Researchers used standard questionnaires to measure these factors at two points: right after a team of doctors discussed the case, and one month after treatment ended. The goal was to better understand what patients experience during this complex care process.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

78 people

The number who actually took part.

Started

Feb 2022

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients are selected by the treating physicians from multidisciplinary consultation in the secondary/tertiary centers Maastricht UMC+ and Radboud UMC.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients diagnosed with a cutaneous squamous cell carcinoma located in the head-neck area (including patients with metastatic or recurrence disease) * requiring a multidisciplinary approach * assessed at the department of dermatology of Maastricht UMC+ or Radboud UMC OR discussed in the multidisciplinary consultation in Maastricht UMC+ or Radboud UMC * and for which treatment of the tumor (primary tumor or metastatic/recurrence) takes places in the Maastricht UMC+ of Radboud UMC * willing to participate voluntarily in the study Exclusion Criteria: * patients younger than 18 years * patients with inadequate understanding of the Dutch language * patients with cognitive impairment or otherwise unable to complete the questionnaires

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cutaneous squamous cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Maastricht University Medical Center +

    Maastricht, Limburg, Netherlands

  • Radboud UMC

    Nijmegen, Gelderland, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.